+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Catalent to buy Juniper Pharmaceuticals for $11.50 per share

05 July 2018
Pharma

U.S. drug contract manufacturer Catalent said it will buy Juniper Pharmaceuticals for $11.50 per share in cash. The offer price represents a premium of about 32 per cent to Juniper Pharmaceuticals’ closing price of $8.70 and values the company at about $127.7 million.

Catalent has a market value of about $5.58 billion.

Juniper Pharmaceuticals shares are up more than 22 per cent since January, when the company said it was exploring strategic alternatives. The deal includes Juniper Pharmaceuticals’ U.K. business, Juniper Pharma Services, and is expected to close in the first quarter of 2019, Catalent said in a statement.

Catalent said it would continue to support Juniper’s Crinone franchise, a progesterone gel which is its single largest revenue source and marketed by Merck outside of the United States. Juniper Pharmaceuticals separately said its board had unanimously approved the deal which represents a total equity value of about $139.6 million on a fully-diluted basis.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to elena.di@visiongain.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes 3D Cell Culture and 3D Bioprinting Market Report 2023-2033

The global 3D Cell Culture and 3D Bioprinting market is valued at US$2,277.2 million in 2023 and is projected to grow at a CAGR of 17.8% during the forecast period 2023-2033.

03 October 2023

Read

Visiongain Publishes Bioreactors Market Report 2023-2033

The global Bioreactors market was estimated to be valued at US$9,977.0 million in 2023 and is expected to register a CAGR of 12.2% from 2023 to 2033.

29 September 2023

Read

Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033

The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.

27 September 2023

Read

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033

The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.

25 September 2023

Read